UK markets open in 7 hours 39 minutes

Dabur India Limited (DABUR.BO)

BSE - BSE Real-time price. Currency in INR
Add to watchlist
509.30+2.10 (+0.41%)
At close: 03:29PM IST
Full screen
Previous close507.20
Open510.00
Bid509.10 x 0
Ask509.35 x 0
Day's range507.55 - 510.20
52-week range489.00 - 596.35
Volume56,251
Avg. volume112,685
Market cap902.5B
Beta (5Y monthly)0.24
PE ratio (TTM)50.48
EPS (TTM)10.09
Earnings date02 May 2024
Forward dividend & yield5.50 (1.08%)
Ex-dividend date10 Nov 2023
1y target estN/A
  • Reuters

    Dabur India flags sluggish demand in March-quarter; shares drop

    Consumer goods maker Dabur India flagged sluggish demand in the March quarter and indicated slowing revenue growth from prior quarters on Thursday, sending shares to a near six-month low. Dabur said it expects mid-single digit percentage revenue growth in the quarter ended March 31, compared to a 7% rise in the December-quarter and 7.3% jump in the quarter before that. Dabur also forecast double-digit percentage growth in constant currency terms for its international business, led by the Middle East and North Africa (MENA) region, Egypt, and Turkey.

  • Reuters

    UPDATE 1-Dabur India's two units dismissed as defendants in hair relaxer lawsuit in US

    Dabur India said on Wednesday a U.S. court had dismissed two of its three subsidiaries as defendants in a lawsuit tying the use of hair relaxer products to ovarian and uterine cancers as well as other health issues. as defendants "for lack of personal jurisdiction" as neither was involved in manufacturing, marketing, distributing or selling hair relaxer products in the United States, the company said in a late filing on Wednesday. However, Dabur's unit Namaste Laboratories continues to be a defendant along with many other industry players such as L'Oreal, Revlon, Luster Products and Avion Industries among others, it added.

  • Reuters

    Dabur India's units face lawsuits in US, Canada alleging products caused cancer

    The consumer goods firm said about 5,400 cases against several companies including its subsidiaries, Namaste Laboratories, Dermoviva Skin Essentials and Dabur International, have been consolidated as a multi-district litigation before a U.S. District Court in Illinois. The units have denied liability and have retained counsel to defend them, the company said.